Epigenomics AG

EANS-News: Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Predictive Biosciences

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

cooperations/molecular diagnostics

Berlin, Germany and Seattle, WA, U.S.A., (euro adhoc) - April 28, 2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, today announced that it has entered into a non-exclusive licensing agreement for its proprietary biomarker mGSTP1 with U.S.-based Predictive Biosciences Incorporated, an innovative and privately held cancer molecular diagnostics company.

Under the agreement, Predictive Biosciences has obtained rights to uses of the GSTP1 DNA methylation biomarker (mGSTP1) to establish and commercialize a molecular-based laboratory-developed test that can help urologists and pathologists better diagnose and manage prostate cancer. Financial terms were not disclosed.

Prostate cancer is the leading cause of cancer death in men in the U.S., with more than 230,000 cases diagnosed annually and more than 1 million prostate biopsies performed each year. Epigenomics and others have demonstrated that methylated DNA of the GSTP1 gene in tissue may indicate the presence of prostate cancer. A test that detects the DNA methylation of the gene GSTP1 in combination with conventional histopathology may augment the accuracy of prostate cancer diagnosis - in particular, in cases with suspicious but inconclusive histology findings or patients with elevated PSA but repeatedly negative biopsies.

"We are pleased that Predictive Biosciences is adding DNA methylation to its menu of molecular diagnostic tests using our technology and biomarker. They share our goal to develop cancer tests that will help physicians achieve improved health outcomes for their patients through better diagnosis of prostate cancer", said Geert Nygaard, CEO of Epigenomics.

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests in development aim at diagnosing cancer at an early stage before symptoms occur and thereby may reduce mortality from this dreaded disease.

Epigenomics' product pipeline contains a validated biomarker for the early detection of colorectal cancer in blood plasma, and further proprietary DNA methylation biomarkers at various stages of development for prostate and lung cancer detection in urine, blood and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the early detection of colorectal cancer in a simple blood sample demonstrated continuously highest performance in multiple clinical studies with in total about 3,500 individuals tested. A large prospective clinical study - PRESEPT - for evaluation of mSEPT9 in a screening population is currently under way (www.presept.net).

For development and global commercialization of in vitro diagnostic test products, Epigenomics pursues a non-exclusive partnering strategy. Strategic diagnostics industry partners include Abbott Molecular, Philips, Sysmex Corporation and Quest Diagnostics Incorporated for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products.

Partners in the health care industry and the biomedical research community can access Epigenomics' portfolio of proprietary DNA methylation technologies and biomarkers protected by more than 150 patent families through research products, Biomarker Services, IVD Development Collaborations, and Licensing. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary in Seattle, WA, U.S.A. For more information, please visit Epigenomics' website at www.epigenomics.com.

Epigenomics legal disclaimer. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN:      DE000A0BVT96
WKN:        A0BVT9
Index:    Prime All Share, Technologie All Share
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Hamburg / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse München / free trade



Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: